In Vivo CAR-T Developer Weitao Bio Secures Over $50 Million in Series A and A+ Financing to Advance GT801 Clinical Development

Apr 29, 2026 12:07 CST Updated 12:07

Vivacta

Cell Therapy Researcher

4Month29Day, Focused on Revolutionary In Vivo (in vivo）CAR-TIVACTA Biotechnology AnnouncesRecently completed in successionAWheel andA+Round of financing, total financing scale exceeding5000Million USDThe two rounds of financing were led by Loyal Valley Capital and Decheng Capital, respectively.OrbiMed(OrbiMed), Hans Health Ventures, Eisai Innovation Fund (Eisai Innovation Inc.), C&D Emerging Investment, and existing shareholders Qiming Venture Partners, Shunxi Fund, Apricot Capital, among other well-known investment institutions, also participated in the investment.

The latest financing will be mainly used for the core products of IVACTA Biotechnology.GT801The clinical trial advancement and registration submission work, as well as the expansion of the research and development team and platform construction, are accelerating IVACTA Biotechnology's progress in vivo.CAR-TGlobal Layout in the Field of Therapy.

Current In VivoCAR-TDevelopment is mainly divided intoNon-viral delivery system (LNPRepresented by) and viral vector systems (represented by lentivirus).GT801Is a product throughTCell TargetingLNPPreferred DeliverymRNAInnovativeanti-CD19In vivoCAR-TProduct.

GT801 LNPProduct Design

Just concluded2026YearAACRAt the conference, IVACTA Biotechnology showcasedGT801Preclinical and Early Clinical Results:

——OptimizedmRNADesign MakesT-LNPPlatform can be used by peoplePBMCIn ChinaExceed14Day'sCARExpression。GT801In the in vitro continuous killing assay, it canContinuous4Completely Clear in TurnsNalm-6Cells, accompanied by stronger release of functional cytokines. Derived from healthy donors, non-Hodgkin's lymphoma patients, and autoimmune disease patients.PBMCIn China,GT801As low as0.1 μgDose Down，24Within hoursAchieve>90%TheBCell Killing。

——In HumanPBMCIn the reconstructed mouse model,GT801In0.1 mpkDose DownCan achieve multiple lymphoid tissuesReceptor Saturation DeliveryAndCARExpression, andOff-target Uptake<1%.Single intravenous administration as low as0.01 mpkCan be achieved>95%TheBCell Clearance。CDXIn the model,GT801Demonstrates potent anti-tumor activity at low doses andShowed enhanced effects after repeated administrationCAR-TAmplification, indicating its good adaptability in vivo and potential for antigen-driven expansion.

——Preliminary clinical data show,GT801InBHigh levels can be induced in patients with cellular hematoma and autoimmune diseases.CARExpression andCAR+ TCell expansion, and verification ofFeasibility of Repeated Dosing。Preliminary efficacy shows that hematological tumor patients have been observed in peripheral blood, bone marrow, and lymph nodes.SignificantBCell Clearance; Patients with autoimmune diseases also exhibitDepthBCell Clearance and Disease Activity Index Improvement, demonstrating positive potential across indications.

IVACTA Biotechnology was founded in2025Year6Month25Day, based on Grail BiotechnologyLNPIn the bodyCAR-TPlatform split (completed last year)Over 100 Million Yuan in Angel Round Financing). It is worth mentioning that,IVACTA Biotechnology has also laid out plans for in vivo applications based on lentiviral vectors.CAR-TPlatform, Core PipelineGT860Focus on Multiple Myeloma.

Specifically,GT860Adopting Mutant TypeVSV-G fusogen, reducing off-target delivery while improving transduction efficiency.Combined with the optimizedT cell binder, AchievePrecision Specificity TargetingTCell Delivery, achieving a balance between high transduction efficiency and good safety. At the same time,GT860In the design ofAlso addedCAR-IGNITE enhancer, AssistTCells Resist Immunosuppression, EnhanceTCell proliferation and tumor-killing ability. InCARIn the selection of structures,GT860AdoptDouble TargetCARStructure, reduce multiple myelomaImmune Escape and Risk of Recurrence, enhance forExtramedullary LesionsControl, extending the patient's recurrence-free survival period.

GT860Lentivirus Product Design

In the past two or three years, inside the bodyCAR-TThe track's popularity has skyrocketed,MNCThe layout in this field continues to upgrade, from initial collaborations to consecutive acquisitions, with transaction amounts constantly rising. Among these,Lilly's Two Deals This Year Are Highly Representative, first inThis Year2Monthly24Hundred Million Dollars to Acquire Based onLNP-oRNAIn vivo technical routeCAR-TCompanyOrnaTherapeutics, and then in4Mid-month with70Billion US dollars(Including32.5 Hundreds of millions of dollars in upfront and subsequent milestone payments)Acquisition of in vivo based on lentivirus technology routeCAR-TCompanyKelonia Therapeutics..Shortly3Within months, consecutive heavy investments have been made,EmbodiesMNCOptimistic about the two major technical routes in different application scenarios。

Currently in vivoCAR-TBoth major technological approaches are in the critical clinical validation phase, within China.CAR-TThe army is also accelerating its progress, from clinical data to collaboration deals, and more good news is expected to be realized in the next two years.

References:

[1]https://grit-bio.com/newsinfo/10869926.html

[2]https://grit-bio.com/newsinfo/11144412.html

[3]https://grit-bio.com/newsinfo/11133574.html

"Frontier π" Column

Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.